NEXUS
GenericsNEXUS is a generic drug manufacturer focused on Metabolic, Infectious Disease, Oncology. Key products include EMERPHED.
NEXUS's Key Drugs
NEXUS's core commercial portfolio centers on POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE 40MEQ, spanning Metabolic and Infectious Disease — its most strategically important drugs approved in the last 15 years.
NEXUS's Recent FDA Approvals
New NDA/BLA approvals for NEXUS over the last two years — novel drugs only, excluding generics and label supplements.
NEXUS's Therapeutic Areas
NEXUS's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NEXUS's Top Competitors
NEXUS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NEXUS Pipeline Snapshot
Active clinical trials for NEXUS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • POTASSIUM CHLORIDE 20MEQ leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2004-03-19
- Latest
- 2025-07-11
- Applications
- 25